Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PYRILAMINE SHOWS STATISTICALLY SIGNIFICANT EFFICACY FOR PREMENSTRUAL CRAMPS

This article was originally published in The Tan Sheet

Executive Summary

PYRILAMINE SHOWS STATISTICALLY SIGNIFICANT EFFICACY FOR PREMENSTRUAL CRAMPS in two studies submitted to FDA by the Nonprescription Drug Manufacturers Association to support the Category I (safe and effective) status of the ingredient. The pooled results of the studies, sponsored by Sterling Winthrop and Chattem, "found statistically significant differences between pyrilamine maleate and placebo" for average cramp cluster symptom scores (comprised of cramps and backache scores), 2.70 for pyrilamine versus 2.98 for placebo, during the four days prior to menstruation.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082736

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel